Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to -$6,784.

  • Immuneering's Gains from Investment Securities fell 122.68% to -$5,469 in Q4 2024 from the same period last year, while for Dec 2024 it was -$10,057, marking a year-over-year decrease of 10.41%. This contributed to the annual value of -$6,784 for FY2024, which is 72.23% down from last year.
  • According to the latest figures from FY2024, Immuneering's Gains from Investment Securities is -$6,784, which was down 72.23% from -$3,939 recorded in FY2023.
  • Over the past 5 years, Immuneering's Gains from Investment Securities peaked at $3.6 million during FY2022, and registered a low of -$6,784 during FY2024.
  • Its 3-year average for Gains from Investment Securities is $1.2 million, with a median of -$3,939 in 2023.
  • Per our database at Business Quant, Immuneering's Gains from Investment Securities spiked by 58.75% in 2021 and then tumbled by 100.11% in 2023.
  • Over the past 5 years, Immuneering's Gains from Investment Securities (Yearly) stood at $1.8 million in 2020, then surged by 58.75% to $2.9 million in 2021, then rose by 24.46% to $3.6 million in 2022, then tumbled by 100.11% to -$3,939 in 2023, then plummeted by 72.23% to -$6,784 in 2024.